Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.43
RTRX's Cash to Debt is ranked higher than
68% of the 1173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. RTRX: 1.43 )
RTRX' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 1.43

Equity to Asset 0.41
RTRX's Equity to Asset is ranked higher than
55% of the 983 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. RTRX: 0.41 )
RTRX' s 10-Year Equity to Asset Range
Min: -3.16   Max: 0.41
Current: 0.41

-3.16
0.41
F-Score: 3
Z-Score: 1.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -58.94
RTRX's Operating margin (%) is ranked lower than
51% of the 1117 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. RTRX: -58.94 )
RTRX' s 10-Year Operating margin (%) Range
Min: 353.41   Max: 2105.03
Current: -58.94

353.41
2105.03
Net-margin (%) -0.90
RTRX's Net-margin (%) is ranked higher than
58% of the 1117 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.55 vs. RTRX: -0.90 )
RTRX' s 10-Year Net-margin (%) Range
Min: 354.18   Max: 2059.37
Current: -0.9

354.18
2059.37
ROE (%) -3.78
RTRX's ROE (%) is ranked higher than
58% of the 1157 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.46 vs. RTRX: -3.78 )
RTRX' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -3.78

ROA (%) -0.35
RTRX's ROA (%) is ranked higher than
60% of the 1183 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.53 vs. RTRX: -0.35 )
RTRX' s 10-Year ROA (%) Range
Min: -375   Max: -142.26
Current: -0.35

-375
-142.26
ROC (Joel Greenblatt) (%) -7959.29
RTRX's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 1178 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.83 vs. RTRX: -7959.29 )
RTRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -54407.87   Max: -28420.55
Current: -7959.29

-54407.87
-28420.55
» RTRX's 10-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RTRX Guru Trades in

RTRX Guru Trades in

Q1 2014

RTRX Guru Trades in Q1 2014

Steven Cohen 3,932 sh (New)
Steven Cohen 1,291,474 sh (New)
» More
2014

RTRX Guru Trades in 2014

Steven Cohen 307,490 sh (-76.19%)
» More
» Details

Insider Trades

Latest Guru Trades with RTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 82.64
RTRX's Forward P/E is ranked higher than
69% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. RTRX: 82.64 )
N/A
P/B 4.90
RTRX's P/B is ranked higher than
61% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. RTRX: 4.90 )
RTRX' s 10-Year P/B Range
Min: 2.66   Max: 4.9
Current: 4.9

2.66
4.9
P/S 9.80
RTRX's P/S is ranked lower than
63% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. RTRX: 9.80 )
RTRX' s 10-Year P/S Range
Min: 5.7   Max: 10.4
Current: 9.8

5.7
10.4
EV-to-EBIT -17.83
RTRX's EV-to-EBIT is ranked lower than
51% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.19 vs. RTRX: -17.83 )
RTRX' s 10-Year EV-to-EBIT Range
Min: -17.6   Max: -9.5
Current: -17.83

-17.6
-9.5
Days Sales Outstanding 40.65
RTRX's Days Sales Outstanding is ranked higher than
91% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 91.38 vs. RTRX: 40.65 )
RTRX' s 10-Year Days Sales Outstanding Range
Min: 0   Max: 0
Current: 40.65

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.20
RTRX's Price/Median PS Value is ranked higher than
83% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. RTRX: 1.20 )
RTRX' s 10-Year Price/Median PS Value Range
Min: 1.05   Max: 1.05
Current: 1.2

Earnings Yield (Greenblatt) -5.60
RTRX's Earnings Yield (Greenblatt) is ranked lower than
52% of the 1170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. RTRX: -5.60 )
RTRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -36.5   Max: 0
Current: -5.6

-36.5
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:17R.Germany,
Retrophin Inc was incorporated as Desert Gateway, Inc. as an Oklahoma corporation on February 8, 2008. On February 14, 2013, the Company changed its name to Retrophin, Inc. The Company is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It is developing Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection, which it refers to as aiding milk let-down, and for the treatment of Schizophrenia and Autism. It is also developing RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone, or ACTH, for the treatment of Infantile Spasms, or IS, and Nephrotic Syndrome, or NS. It is developing sparsentan, formerly known as RE-021, a dual acting receptor antagonist of angiotensin and endothelin receptors, for the treatment of focal segmental glomerulosclerosis, or FSGS. The Company competes with Genentech, GlaxoSmithKline, Roche, Novartis, Pfizer, Boehringer Ingelheim, Sanofi, BioMarin, Sarepta, Vertex, and Jazz Pharmaceuticals. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.
» More Articles for RTRX

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Retrophin, Inc. Nov 28 2014 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Retrophin, Inc. Oct 24 2014 
Largest Insider Buys of the Week Apr 07 2014 
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP Apr 07 2014 
Three CEOs Reporting Large Insider Buys Apr 04 2014 
Steven Cohen Tops GuruFocus' Real Time Picks of the Week Apr 04 2014 
Morning Coffee: See Which Insiders are Buying Apr 04 2014 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 
Weekly CEO Buys Highlight: KMI, CLMS, RTRX, OPK, KO Mar 03 2014 
Weekly CEO Buys Highlight: RSE, RHP, RTRX, CLMS Jan 21 2014 

More From Other Websites
Retrophin to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
Retrophin to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
RETROPHIN, INC. Financials May 19 2015
Coverage initiated on Retrophin by Avondale May 15 2015
10-Q for Retrophin Inc May 13 2015
RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... May 12 2015
Retrophin posts 1Q profit May 11 2015
Retrophin posts 1Q profit May 11 2015
RETROPHIN, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
Retrophin Reports First Quarter 2015 Financial Results May 11 2015
Retrophin Inc Earnings Call scheduled for 4:30 pm ET today May 11 2015
Retrophin Reports First Quarter 2015 Financial Results May 11 2015
10-K for Retrophin Inc May 07 2015
Retrophin Receives FDA Orphan Drug Designation for RE-024 for the Treatment of Pantothenate... May 05 2015
Retrophin Receives FDA Orphan Drug Designation for RE-024 for the Treatment of Pantothenate... May 05 2015
Retrophin Announces FDA Review of IND for RE-024 and Clearance to Proceed With Phase 1 Clinical... Apr 30 2015
Retrophin Announces FDA Review of IND for RE-024 and Clearance to Proceed With Phase 1 Clinical... Apr 30 2015
[Podcast] Biogen is closing in on the holy grail for biotech stocks Apr 29 2015
Retrophin to Report First Quarter 2015 Financial Results Apr 27 2015
Retrophin to Report First Quarter 2015 Financial Results Apr 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK